AIM: To evaluate, whether humoral hepatitis-B-vaccine non-responders also fail to mount a T cell response and to compare these results to normal vaccinees. METHODS: Fourty-seven health care employees were enrolled in this study including all available non-responders (n = 13) with an anti-HBsAg titer < 10 kU/L and all available low-responders (n = 12) with an anti-HBsAg titer < 100 kU/L. Also, 12 consecutive anti-HBsAg negative pre-vaccination subjects were enrolled as well as 10 subjects (+7 from the vaccinated group) with titers > 1000 kU/L as controls. PBMC from all subjects were analyzed by IFN-gamma and IL-4 ELISPOT assays for the presence of hepatitis B surface antigen (HBsAg) reactive T cells. RESULTS: Non-responders and low-responders had no or only very limited T cell responses, respectively. Individuals responding to vaccination with the induction of a high anti-HBsAg titer showed a strong T cell response after the third vaccination. Surprisingly, these individuals showed response even before the first vaccination. T cell response to control antigens and mitogens was similar in all groups. CONCLUSION: Our data suggest that there is no general immune deficiency in non-/low-responders. Thus, we hypothesize that the induction of anti-HBsAg responses by vaccination is significantly dependent on the pre-existing T cell repertoire against the specific antigen rather than the presence of a general T cell defect.
AIM: To evaluate, whether humoral hepatitis-B-vaccine non-responders also fail to mount a T cell response and to compare these results to normal vaccinees. METHODS: Fourty-seven health care employees were enrolled in this study including all available non-responders (n = 13) with an anti-HBsAg titer < 10 kU/L and all available low-responders (n = 12) with an anti-HBsAg titer < 100 kU/L. Also, 12 consecutive anti-HBsAg negative pre-vaccination subjects were enrolled as well as 10 subjects (+7 from the vaccinated group) with titers > 1000 kU/L as controls. PBMC from all subjects were analyzed by IFN-gamma and IL-4 ELISPOT assays for the presence of hepatitis B surface antigen (HBsAg) reactive T cells. RESULTS: Non-responders and low-responders had no or only very limited T cell responses, respectively. Individuals responding to vaccination with the induction of a high anti-HBsAg titer showed a strong T cell response after the third vaccination. Surprisingly, these individuals showed response even before the first vaccination. T cell response to control antigens and mitogens was similar in all groups. CONCLUSION: Our data suggest that there is no general immune deficiency in non-/low-responders. Thus, we hypothesize that the induction of anti-HBsAg responses by vaccination is significantly dependent on the pre-existing T cell repertoire against the specific antigen rather than the presence of a general T cell defect.
Authors: M G Chedid; H Deulofeut; D E Yunis; M L Lara-Marquez; M Salazar; R Deulofeut; Z Awdeh; C A Alper; E J Yunis Journal: Hum Immunol Date: 1997-11 Impact factor: 2.850
Authors: T Höhler; C U Meyer; A Notghi; B Stradmann-Bellinghausen; P M Schneider; R Starke; F Zepp; R Sänger; R Clemens; K H Meyer zum Büschenfelde; C Rittner Journal: Hum Immunol Date: 1998-04 Impact factor: 2.850
Authors: S Thoelen; P Van Damme; C Mathei; G Leroux-Roels; I Desombere; A Safary; P Vandepapeliere; M Slaoui; A Meheus Journal: Vaccine Date: 1998-04 Impact factor: 3.641
Authors: M H Chang; C J Chen; M S Lai; H M Hsu; T C Wu; M S Kong; D C Liang; W Y Shau; D S Chen Journal: N Engl J Med Date: 1997-06-26 Impact factor: 91.245
Authors: C L Cooper; H L Davis; M L Morris; S M Efler; M Al Adhami; A M Krieg; D W Cameron; J Heathcote Journal: J Clin Immunol Date: 2004-11 Impact factor: 8.317
Authors: Casey P Shannon; Travis M Blimkie; Rym Ben-Othman; Nicole Gladish; Nelly Amenyogbe; Sibyl Drissler; Rachel D Edgar; Queenie Chan; Mel Krajden; Leonard J Foster; Michael S Kobor; William W Mohn; Ryan R Brinkman; Kim-Anh Le Cao; Richard H Scheuermann; Scott J Tebbutt; Robert E W Hancock; Wayne C Koff; Tobias R Kollmann; Manish Sadarangani; Amy Huei-Yi Lee Journal: Front Immunol Date: 2020-11-30 Impact factor: 7.561